MDT-AP-0448
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 13
- sex
- F
- new_clusters
- C2
- umap1_2d
- 2.586127509
- umap2_2d
- 0.908390275
- umap1_3d
- -0.7008491
- umap2_3d
- -2.865582633
- umap3_3d
- -1.554836359
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.480
- WNT_BETA_CATENIN_SIGNALING+0.280
- G2M_CHECKPOINT+0.270
- E2F_TARGETS+0.220
- KRAS_SIGNALING_DN+0.200
- HEME_METABOLISM+0.160
- TGF_BETA_SIGNALING+0.160
- ANGIOGENESIS+0.120
- MITOTIC_SPINDLE+0.120
- MTORC1_SIGNALING+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- INTERFERON_GAMMA_RESPONSE-0.340
- ALLOGRAFT_REJECTION-0.300
- APICAL_SURFACE-0.270
- COMPLEMENT-0.230
- PROTEIN_SECRETION-0.200
- INFLAMMATORY_RESPONSE-0.190
- OXIDATIVE_PHOSPHORYLATION-0.190
- TNFA_SIGNALING_VIA_NFKB-0.190
- APOPTOSIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1330 | Med | Medulloblastoma | 0.800 |
| 2 | MDT-AP-0360 | Med | Medulloblastoma | 0.794 |
| 3 | SRR11296886 | — | — | 0.783 |
| 4 | SRR12475126 | — | — | 0.763 |
| 5 | f2c3b90a.7e75.4a2a.925e.29eb9a2acac2 | — | cohortA3 | 0.759 |
| 6 | MDT-AP-1377 | Med | Medulloblastoma | 0.756 |
| 7 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.753 |
| 8 | DRR168539 | — | — | 0.752 |
| 9 | TCGA-CV-6956-01A-21R-2016-07 | — | — | 0.748 |
| 10 | MNG497 | — | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |